Errol De Souza

Dr. De Souza is a seasoned R&D and business leader with broad experience – from large pharma to start ups – in the discovery and development of therapeutics for the treatment of central nervous system (CNS) disorders. Dr. De Souza is currently the executive chairman of Bionomics Limited and a member of the board of directors of Royalty Pharma and Catalyst Biosciences. Previously, Dr. De Souza founded Neurocrine Biosciences, Inc., served as CEO of numerous publicly traded and private companies, including Biodel, Inc., Synaptic Pharmaceutical Corp., Archemix Corp. and Neuropore Therapies, Inc. In addition, he led CNS R&D at DuPont Merck and US R&D at Aventis. Dr. De Souza received a B.A. in physiology and a Ph.D. in endocrinology from the University of Toronto.